High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.
List view / Grid view
Stephen J. Capuzzi and David C. Morris (Eshelman School of Pharmacy - University of North Carolina Chapel Hill)
Filter the results